SCHEMBL5262085

SCHEMBL5262085

COC(=O)[C@H](Cc1ccc(Nc2nccc3cnccc23)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK5 Q9Y337 1/20 0.44
NPR3 P17342 2/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C8 P10632 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
CTSS P25774 6/20 0.39
CTSK P43235 5/20 0.39
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39
HDAC8 Q9BY41 1/20 0.38
PTPN1 P18031 1/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
P2RX7 Q99572 2/20 0.38
PTPRB P23467 1/20 0.38
CYP17A1 P05093 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262088 1.00 KLK5 (0.44) KLK5NPR3CYP3A4CYP2C8CYP2C9
SCHEMBL5147793 0.93 ALDH1A1 (0.39) KLK5NPR3CYP3A4CYP2C8CYP2C9
SCHEMBL7104303 0.92 ITGB3 (0.48) NPR3CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL2978498 0.92 ITGB3 (0.48) NPR3CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL2990954 0.86 TACR1 (0.40) KLK5NPR3CYP3A4CYP2C8CYP2C9
SCHEMBL2990961 0.86 TACR1 (0.40) KLK5NPR3CYP3A4CYP2C8CYP2C9
SCHEMBL5259419 0.84 ITGB3 (0.43) KLK5ITGB3ITGA2BCTSSCTSK
SCHEMBL5259415 0.84 ITGB3 (0.43) KLK5ITGB3ITGA2BCTSSCTSK
SCHEMBL7259564 0.82 KLK5 (0.44) KLK5NPR3CYP3A4CYP2C8CYP2C9
SCHEMBL5262134 0.81 CIT (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070238763-A1 Urea derivatives as integrin a4 antagonists LABORATORIOS ALMIRALL, S.A. 2007-10-11 US disclosed
EP-1383750-B1 UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS ALMIRALL LAB (ES) 2007-09-26 EP disclosed
US-7253171-B2 Urea derivatives as integrin α4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-07 US disclosed
US-20040142982-A1 Urea derivatives as integrin alpha 4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142982-A1 Urea derivatives as integrin alpha 4 antagonists ITGA4, ITGB4, ITGA1 KLK5 4326/4885NPR3 2494/4885CYP3A4 1421/4885
US-20070238763-A1 Urea derivatives as integrin a4 antagonists ITGB4, ITGA4, ITGB7 KLK5 3000/4885NPR3 4157/4885CYP3A4 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.